Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      Indoco Remedies Goa unit receives approval from UK health regulator

      Indoco Remedies Goa unit receives approval from UK health regulator

      Ruby Khatun Khatun13 May 2017 12:50 PM IST
      Mumbai: Pharma firm Indoco Remedies said it has received approval from the UKs health regulator for its solid dosages manufacturing plant in Goa."We...
      Nanotechnology Startup Log 9 Raises Pre Series A Funding from Delhi Based VC firm, GEMs

      Nanotechnology Startup Log 9 Raises Pre Series A Funding from Delhi Based VC firm, GEMs

      Ruby Khatun Khatun13 May 2017 12:46 PM IST
      A unique idea in the Nanotechnology domain, Log 9 Materials has raised an undisclosed amount in a pre-series-A funding from GEMs, a Delhi based...
      Eli Lilly migraine treatment meets main goal in late-stage studies

      Eli Lilly migraine treatment meets main goal in late-stage studies

      Ruby Khatun Khatun13 May 2017 12:44 PM IST
      Eli Lilly and Co said on Friday patients with episodic and chronic migraine reported fewer debilitating headaches after using the drugmaker's...
      AstraZeneca shares surge after key drug shows promise in lung cancer trial

      AstraZeneca shares surge after key drug shows promise in lung cancer trial

      Ruby Khatun Khatun13 May 2017 12:44 PM IST
      LONDON: A trial of AstraZeneca's key immunotherapy drug durvalumab showed it reduced disease progression in lung cancer patients, sending the...
      Max Founder Analjit to infuse Rs 300 cr in Max India in lieu of warrants

      Max Founder Analjit to infuse Rs 300 cr in Max India in lieu of warrants

      Ruby Khatun Khatun12 May 2017 12:43 PM IST
      New Delhi: Max India Limited (Max India) announced that it will raise funds from its Sponsor, Max Group’s Founder and Chairman Emeritus Mr. Analjit...
      NPPA revises rates of 6 drugs, fixes price of 1 medicine, check out details

      NPPA revises rates of 6 drugs, fixes price of 1 medicine, check out details

      Ruby Khatun Khatun12 May 2017 12:17 PM IST
      New Delhi: Drug price regulator NPPA has revised the prices of six essential drugs, including the ones used for treatment of irritable bowel syndrome,...
      Nearly 1 in 3 drugs have safety concerns after FDA approval: JAMA

      Nearly 1 in 3 drugs have safety concerns after FDA approval: JAMA

      Ruby Khatun Khatun12 May 2017 12:13 PM IST
      How often are safety concerns raised about a drug after it's been approved by the FDA? Nicholas Downing, MD, of the Department of Medicine at Brigham...
      World Health Organisation wants transparency, market revamp for fairer drug pricing

      World Health Organisation wants transparency, market revamp for fairer drug pricing

      Ruby Khatun Khatun12 May 2017 12:11 PM IST
      The world needs greater transparency on the pricing of medicines, and an overhaul of some approaches, in order to increase access to life-saving...
      Novo Nordisk bets on new obesity drug recipes

      Novo Nordisk bets on new obesity drug recipes

      Ruby Khatun Khatun12 May 2017 12:09 PM IST
      LONDON: Hit by pricing pressure in its core insulin business, Danish drugmaker Novo Nordisk is looking at new treatments for obesity - a major cause...
      Pfizer strikes deal with Sangamo, broadening hemophilia pipeline

      Pfizer strikes deal with Sangamo, broadening hemophilia pipeline

      Ruby Khatun Khatun12 May 2017 11:47 AM IST
      U.S. drugmaker Pfizer Inc said on Wednesday it reached an agreement with Sangamo Therapeutics Inc for rights to its gene therapy programs to treat the...
      Stent Price Cap: Govt Slams Boston Scientific plea to increase cap to Rs 75,000

      Stent Price Cap: Govt Slams Boston Scientific plea to increase cap to Rs 75,000

      Ruby Khatun Khatun11 May 2017 1:08 PM IST
      New Delhi: Boston Scientific Corp stands to lose millions of dollars on its high-end heart stent in India after a government panel rejected its...
      Natco Pharma launches generic hepatitis C drug in India

      Natco Pharma launches generic hepatitis C drug in India

      Ruby Khatun Khatun11 May 2017 12:01 PM IST
      New Delhi: Natco Pharma said it has launched generic sofosbuvir 400 mg/velpatasvir 100 mg tablets, used for treatment of chronic hepatitis C, in...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok